Meronem Iv (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by susceptible bacteria.

• Complicated intra‑abdominal infections: provides bactericidal activity to eradicate the pathogen and resolve intra‑abdominal sepsis.
• Complicated urinary tract infections: eliminates causative organisms and restores urinary tract sterility.
• Hospital‑acquired pneumonia: achieves rapid bacterial clearance in patients with nosocomial lung infection.
• Ventilator‑associated pneumonia: targets resistant pathogens to improve respiratory outcomes.
• Severe sepsis and septic shock: offers systemic bacterial killing to support hemodynamic recovery.
• Meningitis caused by susceptible organisms: penetrates the cerebrospinal fluid to eradicate central nervous system infection.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis and bacterial death. The molecule is stable against most β‑lactamases, giving it activity against a wide range of Gram‑positive, Gram‑negative and anaerobic organisms.

Adverse reactions may occur with any antimicrobial therapy and should be monitored during treatment.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Infusion site reactions: redness, pain or swelling at the injection site.

Serious or Rare Side Effects

• Clostridioides difficile‑associated colitis: severe diarrhea requiring medical intervention.
• Anaphylaxis: rapid onset of hypersensitivity with respiratory or cardiovascular compromise.
• Seizures: especially in patients with renal impairment or high plasma concentrations.
• Renal toxicity: elevated creatinine or reduced urine output.
• Severe allergic reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Thrombophlebitis: inflammation of the vein used for infusion.

Careful assessment and monitoring are required before and during therapy with Meropenem.

• Renal impairment: adjust dose based on creatinine clearance to avoid accumulation.
• History of seizures: monitor neurologic status, especially in patients with CNS disorders.
• Known hypersensitivity to carbapenems or β‑lactams: avoid use to prevent allergic reactions.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Concomitant valproic acid: may reduce serum levels of valproate, risking seizure breakthrough.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces valproate plasma concentrations, potentially precipitating seizures.
• Other carbapenems: concurrent use may increase risk of neurotoxicity without added benefit.
• High‑dose aminoglycosides: combined nephrotoxic potential may impair renal function.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may exacerbate renal impairment; monitor kidney function.
• NSAIDs: additive renal stress, especially in dehydrated patients.
• Anticoagulants (e.g., warfarin): possible alteration of INR; check coagulation parameters regularly.